Rockefeller Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.9K Hold
3,380
– – ﹤0.01% 3795
2026
Q2
$21.1K Sell
3,380
-3,768
-53% -$16.3K ﹤0.01% 3717
2026
Q1
$20.2K Buy
7,148
+5,714
+398% +$19.4K ﹤0.01% 3713
2025
Q4
$4.66K Buy
+1,434
New +$4.83K ﹤0.01% 4092
2023
Q1
– Sell
-721
Closed -$10K – 3165
2022
Q4
$10K Sell
721
-4,879
-87% -$76.8K ﹤0.01% 3078
2022
Q3
$142K Buy
+5,600
New +$141K ﹤0.01% 1810
2022
Q2
– Sell
-115
Closed -$4K – 4289
2022
Q1
$4K Buy
115
+45
+64% +$1.51K ﹤0.01% 3426
2021
Q4
$2K Hold
70
– – ﹤0.01% 3552
2021
Q3
$3K Hold
70
– – ﹤0.01% 3349
2021
Q2
$2K Buy
+70
New +$2.71K ﹤0.01% 3257

Other funds holding MRVI

Rockefeller Capital Management's MRVI Position: Q3 2026 in Review

Rockefeller Capital Management held its Maravai LifeSciences (MRVI) position steady in Q3 2026 at 3,380 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3795.

Rockefeller Capital Management first reported a position in MRVI in Q2 2021 and has held it in 10 quarters since. The position peaked at $142K in Q3 2022. 202 funds tracked by Wall St. Rank hold MRVI as of Q3 2026.

  • Rockefeller Capital Management held 3,380 shares of Maravai LifeSciences worth $25.9K as of Q3 2026.
  • Rockefeller Capital Management left its Maravai LifeSciences share count unchanged in Q3 2026.
  • Maravai LifeSciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3795 holding.
  • Rockefeller Capital Management first reported a position in Maravai LifeSciences in Q2 2021 and has held it in 10 quarters since.
  • Rockefeller Capital Management's Maravai LifeSciences position peaked at $142K in Q3 2022.
  • 202 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.